Susquehanna International Group
PHAT icon

Susquehanna International Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Susquehanna International Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.6M Buy
323,800
+6,200
+2% +$78.3K ﹤0.01% 4880
2025
Q4 		$5.27M Buy
317,600
+262,300
+474% +$3.75M ﹤0.01% 3934
2025
Q3 		$651K Sell
55,300
-499,600
-90% -$5.16M ﹤0.01% 8375
2025
Q2 		$5.32M Buy
554,900
+524,600
+1,731% +$2.9M ﹤0.01% 3861
2025
Q1 		$190K Buy
30,300
+4,400
+17% +$26.7K ﹤0.01% 10988
2024
Q4 		$210K Buy
25,900
+3,100
+14% +$38.4K ﹤0.01% 10627
2024
Q3 		$412K Sell
22,800
-440,100
-95% -$6.15M ﹤0.01% 8934
2024
Q2 		$4.77M Buy
462,900
+448,800
+3,183% +$4.62M ﹤0.01% 3518
2024
Q1 		$150K Buy
14,100
+1,300
+10% +$11K ﹤0.01% 10906
2023
Q4 		$117K Sell
12,800
-68,400
-84% -$589K ﹤0.01% 11202
2023
Q3 		$842K Sell
81,200
-71,200
-47% -$977K ﹤0.01% 7029
2023
Q2 		$2.18M Sell
152,400
-39,300
-21% -$453K ﹤0.01% 4974
2023
Q1 		$1.37M Buy
+191,700
New +$1.68M ﹤0.01% 6023
2022
Q4 		– Sell
-76,100
Closed -$843K – 13369
2022
Q3 		$843K Buy
76,100
+600
+0.8% +$5.72K ﹤0.01% 7084
2022
Q2 		$637K Buy
75,500
+40,600
+116% +$417K ﹤0.01% 7671
2022
Q1 		$475K Buy
+34,900
New +$564K ﹤0.01% 9125
2021
Q3 		– Sell
-10,000
Closed -$339K – 13352
2021
Q2 		$339K Buy
+10,000
New +$358K ﹤0.01% 10504
2021
Q1 		– Sell
-10,800
Closed -$359K – 12690
2020
Q4 		$359K Buy
+10,800
New +$438K ﹤0.01% 8924

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Susquehanna International Group's PHAT Position: Q1 2026 in Review

Susquehanna International Group reduced its Phathom Pharmaceuticals (PHAT) stake by 83% in Q1 2026, selling an estimated $5.76M and leaving 92,979 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #7809.

Susquehanna International Group first reported a position in PHAT in Q4 2020 and has held it in 15 quarters since. The position peaked at $9.11M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Susquehanna International Group held 92,979 shares of Phathom Pharmaceuticals worth $1.03M as of Q1 2026.
  • Susquehanna International Group sold 456,192 Phathom Pharmaceuticals shares in Q1 2026, an estimated $5.76M.
  • Phathom Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7809 holding.
  • Susquehanna International Group first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • Susquehanna International Group's Phathom Pharmaceuticals position peaked at $9.11M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.